Jonathan Heeney

Scientific lead; founder of DIOSynVax

Appears in 1 story

Education: University of Cambridge, United States National Institutes of Health, University of Guelph

Last updated Nov 6, 2026

Stories

AI-designed universal coronavirus vaccine clears first human safety trial

New Capabilities

Leading the program into a planned Phase 2 trial

Thirty-nine healthy volunteers received the Cambridge vaccine and none had a serious side effect. Their blood carried antibodies that bound a wide range of sarbecoviruses, the family that includes SARS-CoV-2, the original SARS virus and related bat viruses. Neutralizing activity was modest and uneven.

Updated 5 days ago